Pharma and Biotech
Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | n/a | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | n/a | n/a |
Pr/Book | 2.7 |
Latest | F'cast | |
---|---|---|
Revenue | n/a | n/a |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-20 | 0.52 | (0.45) | (0.65)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-21 | 0.22 | (0.95) | (1.36)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-22 | 0.54 | (2.70) | (2.61)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-23 | 0.59 | (3.12) | (3.00)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-24 | n/a | (1.45) | (0.12)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Synthesis of development candidate for SVN-SDN-014 | 05-Jun-2025 | 07:00 | RNS |
Notice of Annual General Meeting | 03-Jun-2025 | 16:30 | RNS |
Appointment of Prof. David Nutt as CSO | 03-Jun-2025 | 07:00 | RNS |
Graft Polymer to buy Awakn in £4.98m deal | 16-Dec-2024 | ShareCast |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 0.14p |
Change Today | 0.008p |
% Change | 5.56 % |
52 Week High | 0.78p |
52 Week Low | 0.12p |
Volume | 137,144,501 |
Shares Issued | 5,909m |
Market Cap | £8.42m |
Beta | 0.01 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:31 | 17,500,000 @ 0.14p |
16:25 | 1,533,387 @ 0.14p |
16:20 | 103,601 @ 0.15p |
16:20 | 5,000 @ 0.14p |
16:20 | 7,000 @ 0.14p |
CEO | Anthony Tennyson |
Chair | Dennis Purcell |
Finance Director | Ryan Neats |
You are here: research